Press releases

2019-11-13 | Regulatory

Vicore Pharma has completed a directed share issue of approximately SEK 125 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, THE UNITED KINGDOM, CANADA, HONGKONG, JAPAN, SWITZERLAND, NEW ZEALAND, SINGAPORE, SOUTH AFRICA,… Read more

2019-11-12 | Regulatory

Vicore Pharma intends to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, THE UNITED KINGDOM, CANADA, HONGKONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, THE… Read more

2019-11-08 | Regulatory

Interim report January-September 2019

Gothenburg, November 8, 2019 - Vicore Pharma Holding AB (publ) publish the interim report for the third quarter 2019.  Read more

2019-10-03 | Regulatory

Vicore Pharma announces the Nomination Committee for the 2020 Annual General Meeting

Gothenburg, October 3, 2019 – Vicore Pharma Holding AB (publ) has appointed the Nomination Committee for the 2020 Annual General Meeting. The three largest shareholders… Read more

2019-10-01

Update on progress in clinical lead program VP01 (C21)

Gothenburg, October 1, 2019 – Following the successful dose escalation phase I study, Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative… Read more

2019-09-16 | Regulatory

Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

Gothenburg,September 16, 2019- On September 11, 2019, Vicore Pharma Holding AB (publ) (”Vicore” or the “Company”)  announced that Nasdaq Stockholm’s listing committee had approved that the Company’s… Read more

2019-09-11 | Regulatory

Vicore Pharma has been approved for listing on Nasdaq Stockholm

Gothenburg, September 11, 2019 – Nasdaq Stockholm’s listing committee has approved Vicore Pharma Holding AB (publ)’s (”Vicore”) application to be listed on Nasdaq Stockholm’s main… Read more

2019-08-23 | Regulatory

Interim report April-June 2019

Mölndal, August 23, 2019 – Vicore Pharma Holding (publ) publish the interim report for the second quarter 2019. Read more

2019-05-15 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) (”Vicore Pharma”) on 15 May 2019. Read more

2019-05-15 | Regulatory

Interim report January - March 2019

Mölndal, May 15, 2019 – Vicore Pharma Holding (publ) publishes the interim report for the first quarter 2018. Read more

2019-04-23 | Regulatory

Vicore Pharma announces systemic sclerosis as the second indication for VP01

Mölndal, April 23, 2019 - Vicore Pharma AB (publ) a leading rare diseases pharmaceutical company today announces that it has selected diffuse systemic sclerosis (dSSc)… Read more

2019-04-12 | Regulatory

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, with registered office in Mölndal, are summoned to the Annual General Meeting on Wednesday… Read more

2019-04-12 | Regulatory

Vicore Pharma's Annual Report 2018 published

Mölndal, April 12, 2019 - Vicore Pharma Holding AB (publ) announces today that the annual report for 2018 has been published and is available on… Read more

2019-03-15 | Regulatory

Year-end report 2018

Mölndal, March 15, 2019 – Vicore Pharma Holding (publ) (ticker: VICO) publish the year-end report for 2018 Read more

2019-02-13

Vicore Pharma postpones publication of year-end report

Mölndal, February 13, 2019 - Vicore Pharma Holding AB (publ) has decided to postpone the publication of the year-end report for 2018. The year-end report… Read more

2018-11-30 | Regulatory

Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)

The shareholders in Vicore Pharma Holding AB (publ), reg. no. 556680-3804 (the “Company”), are hereby summoned to attend an Extraordinary General Meeting (“EGM”) on Monday… Read more

2018-11-30 | Regulatory

Vicore Pharma’s Board of Directors has resolved on a directed share issue of around SEK 160 million to finance the continued development of the drug development programs VP01 and VP02

NOT FOR DISTRIBUTION OR PUBLIC RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UK, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN… Read more

2018-11-08 | Regulatory

Interim report July-September 2018

Mölndal, November 8, 2018 – Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the third quarter 2018. Read more

2018-11-01

Vicore Pharma’s rights issue registered – conversion of BTA to shares

Not to be released, publication or distribution, directly or indirectly, in or to the United States, Australia, Hong Kong, Singapore, Canada, Japan, New Zealand or… Read more

2018-10-22 | Regulatory

Göran Wessman resigns from the Board – joins the Nomination Committee now appointed in Vicore Pharma Holding

Mölndal, October 22, 2018 - Due to personal reasons, Göran Wessman has chosen to resign from the Board of Directors of Vicore Pharma Holding AB… Read more

2018-10-09 | Regulatory

Rights issue in Vicore oversubscribed by 33 percent – The company receives SEK 82.4M

Mölndal, October 9, 2018 - Vicore Pharma Holding AB (publ) (”Vicore” or the ”Company”) has completed the new share issue with pre-emption rights for existing… Read more

2018-09-26

Vicore Pharma postpones publication of interim report

Mölndal, September 26, 2018 - Vicore Pharma Holding AB (publ) has decided to postpone the publication of the interim report for the third quarter 2018.… Read more

2018-09-18

Vicore publishes prospectus and new financial information contained in the prospectus

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, HONG KONG, SWITZERLAND, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR… Read more

2018-09-17

Vicore Pharma strengthens team with two key hires to support focus on rare lung disease

September 17, 2018 - Vicore Pharma (publ) announced today it has appointed Rohit Batta as Chief Medical Officer effective November 26 and Göran Tornling as… Read more

2018-09-12

Information relating to the decided rights issue in Vicore Pharma

The Board of Directors of Vicore Pharma Holding AB (publ) (”Vicore”) informs about the time plan for the rights issue (the ”Rights issue”) that was… Read more

2018-09-10 | Regulatory

Vicore Pharma expands VP01 (C21) clinical program to enable functional read out

Vicore Pharma (publ) today announced that it will expand its clinical program of lead compound C21, for the treatment of idiopathic pulmonary fibrosis (IPF), to… Read more

2018-08-30 | Regulatory

Carl-Johan Dalsgaard Appointed New CEO of Vicore Pharma

The board of directors of Vicore Pharma Holding AB (”Vicore”) has on August 29, 2018 appointed Dr. Carl-Johan Dalsgaard as new CEO of Vicore. Carl-Johan… Read more

2018-08-24 | Regulatory

Interim report April-June 2018

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the second quarter 2018. Read more

2018-08-15

Last day of trading including right to dividend shares in I-Tech AB

Today, Wednesday, August 15, is the last day Vicore Pharma Holding (publ) (ticker: VICO) share is traded including the right to dividend shares in I-Tech… Read more

2018-08-13 | Regulatory

Press release from the Extra General Meeting August 13, 2018

The Extra General Meeting (EGM) of Vicore Pharma Holding AB (publ) was held today August 13, 2018. The EGM passed resolutions regarding, among other thing,… Read more

2018-07-14

Notice of Extraordinary General Meeting of Vicore Pharma Holding AB (publ)

The shareholders in Vicore Pharma Holding AB (publ), reg. no. 556680-3804 (the “Company”), are hereby summoned to attend an Extraordinary General Meeting (“EGM”) on Monday… Read more

2018-07-03 | Regulatory

Vicore Pharma and HealthCap create a leading drug development company focused on severe lung diseases

Vicore Pharma Holding AB (publ) ("Vicore" or "The Company") has entered into an agreement to acquire INIM Pharma AB ("INIM"), a Swedish biopharmaceutical company developing… Read more

2018-05-11 | Regulatory

Summons to attend the Annual General Meeting of Vicore Pharma Holding AB (publ).

The shareholders in Vicore Pharma Holding AB (publ), 556680-3804, are hereby summoned to attend the Annual General Meeting on June 13, 2018 at 4:00 p.m.… Read more

2018-05-08 | Regulatory

Interim report January-March 2018

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the first quarter 2018. Read more

2018-04-18 | Regulatory

Vicore Pharma receives approval to start Phase IIa study in IPF

Vicore Pharma Holding (publ) (ticker: VICO) today announces the approval from the British Medicines Agency MHRA and the Ethics Committee for London and Surrey to… Read more

2018-04-12 | Regulatory

Vicore Pharma publish annual report for 2017

Vicore Pharma Holding (publ) (ticker: VICO) can today announce that the annual report for 2017 is now available on the company's website; www.vicorepharma.com Read more

2018-04-06 | Regulatory

Summons to attend the Annual General Meeting of Vicore Pharma Holding AB (publ)

The shareholders in Vicore Pharma Holding AB (publ), 556680-3804, are hereby summoned to attend the Annual General Meeting on Tuesday, May, 8, 2018 at 3:00… Read more

2018-03-21

Frontiers in Physiology publish data with C21 on pulmonary fibrosis

Vicore Pharma Holding (publ) (ticker:VICO) can today announce that preclinical data with C21 demonstrating good results has been accepted for publication. Read more

2018-02-21 | Regulatory

Year-end report 2017

Read more

2018-02-08 | Regulatory

Vicore Pharma acquires shares in I-Tech

Vicore Pharma Holding AB (publ) (ticker: VICO) announces a share increase in I-Tech AB. Read more

2018-01-26

Highlights from new publications on C21 and the AT2 receptor

Vicore Pharma (publ) (ticker VICO) has today published an updated reference list on the latest preclinical studies with the drug candidate C21. Two recent published… Read more

2017-12-22 | Regulatory

Vicore Pharma increases its holding in I-Tech AB

Vicore Pharma Holding (publ) (ticker:VICO) has increased its holding in I-Tech through a share issue. Read more

2017-12-22 | Regulatory

Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding (publ) (ticker:VICO) announces that an application to start a Phase IIa study with C21 in patients suffering from Idiopathic Pulmonary Fibrosis has… Read more

2017-11-08 | Regulatory

Vicore Pharma´s board member Göran Arvidson has passed away

Vicore Pharma Holding (publ) (ticker:VICO). It is with great regret we today inform of board member Göran Arvidson sudden and unexpected death. Read more

2017-11-01

Vicore Pharma to Attend Two Investor Conferences in London in November 2017

Vicore Pharma will present at the Biotech and Money Inv€$tival Showcase in partnership with Jefferies and host one-to-one meetings at the Jefferies 2017 London Healthcare… Read more

2017-10-19 | Regulatory

Interim report July-September 2017

Vicore Pharma Holding publish the interim report for the third quarter, 2017. Read more

2017-10-09

Clinical potential of C21 highlighted in review publications

Vicore Pharma (publ) (ticker VICO) has today published an updated reference list on the latest studies with the drug candidate C21. Three recent review articles,… Read more

2017-10-02 | Regulatory

Phase I extension study demonstrates beneficial effects on lipid metabolism with C21

Vicore Pharma AB (publ) (ticker: VICO) can today announce positive results from the in-depth analysis of the Phase I extension study with its candidate drug… Read more

2017-08-24 | Regulatory

Interim report April-June 2017

Vicore Pharma Holding publish the interim report for the second quarter, 2017. Read more

2017-08-17 | Regulatory

Results from extension study with C21 show safety, tolerability and indicate effects on lipid metabolism

Vicore Pharma AB (publ) (ticker: VICO) can today announce positive results from the Phase I extension study with its candidate drug C21. Read more

2017-06-01 | Regulatory

Vicore Pharma makes strategic recruitments

Vicore Pharma AB (publ) (ticker: VICO) today announced that they strengthen the organization with three new key recruitments. Read more

2017-05-17 | Regulatory

Newly appointed Chairman of the Board increases his holdings in Vicore Pharma Holding

Newly appointed Chairman of the Board of Vicore Pharma Holding (ticker: VICO), Leif Darner has acquired 100,000 shares from Protem Wessman AB, controlled by Göran… Read more

2017-05-17

Vicore Pharma to participate in Jefferies Healthcare Conference

Vicore Pharma AB (ticker: VICO), a global biotech company developing drugs that act through the AT2 receptor in the renin angiotensin system, today announced that… Read more

2017-05-10 | Regulatory

Press release from the Annual General Meeting May 10, 2017

The Annual General Meeting (AGM) of Vicore Pharma Holding AB (publ) was held today May 10, 2017. The AGM passed resolutions regarding, among other thing,… Read more

2017-05-10 | Regulatory

Interim report January-March 2017

Vicore Pharma Holding publish the interim report for the period January-March, 2017. Read more

2017-04-06 | Regulatory

Vicore Pharma Holding publish annual report for 2016

We achieved the milestones we determined for 2016. Now, we will continue to develop C21 into a future drug for the treatment of idiopathic pulmonary… Read more

2017-04-03 | Regulatory

Notice of Annual General Meeting in Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, hereby gives notice to shareholders to attend the Annual General Meeting on Wednesday 10 May 2017 at… Read more

2017-03-08

C21 has a strong impact on several markers in an in vitro study for pulmonary fibrosis

A BioMAP® report comparing Vicore Pharma’s drug candidate C21 to two approved drugs for IPF shows strong and competitive results Read more

2017-02-23

Vicore Pharma resolves on directed share issues and publish notice for an extraordinary shareholders’ meeting

The Board of Directors of Vicore Pharma Holding AB has resolved on two directed share issues, one pursuant to authorization from the general annual meeting… Read more

2017-02-15

Vicore Pharma extends research portfolio with new drug molecules

Vicore Pharma has today announced that it has developed new drug molecules that selectively stimulate the AT2 receptor (AT2R agonism) in the Renin-Angiotensin-System. Based on… Read more

2017-01-27

Vicore Pharma is granted orphan drug designation from FDA for the treatment of IPF

US Food and Drug Administration (FDA) has granted orphan drug status for Vicore Pharma's lead compound C21 for the treatment of idiopathic pulmonary fibrosis (IPF). Read more

2016-11-09

Phase I-study succesfully completed

Vicore Pharma has completed the two-part Phase I study in healthy male volunteers and have thereby passed an important milestone in the company's development. Read more

2016-09-27

C21 may protect the heart from chemotherapy toxicity

The first study showing a cardioprotective effect of the AT2-receptor agonist, C21, in cancer treatment. Read more

2016-08-01

Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF

The European Commission has granted orphan drug status for Vicore Pharma’s lead compound C21 for the treatment of idiopathic pulmonary fibrosis (IPF). Read more

2016-06-30

New research data with C21 on diabetes

- Dr Chow et al, Melbourne: C21 has an anti-atherosclerotic effect in animal models with diabetes. - Dr Liu et al, Beijing: C21 protects the… Read more

2016-06-13

Successful conclusion of the first Phase I study with C21

Vicore Pharma reports the conclusion of the clinical conduct of its first Phase I trial with C21. The study was conducted on male healthy volunteers… Read more

2016-04-15

Selektope wins European Marine Engineering award

Vicore Pharma Holdings financial asset, I-Tech recently won a prestigious prize arranged by the European Marine Engineering awards for their antifouling substance, Selektope®. Read more… Read more

2015-11-05

I-Tech seals market acceptance for Selektope

Vicore Pharma H., holds 17% of the shares in I-Tech AB. Final sign-off of the antifouling active substance Selektope® by the European Commission coincides the… Read more

2015-07-14

Selektope voted for European Union approval

The antifouling biocide Selektope®has been endorsed by the EU Standing Committee on Biocidal Products and will be approved EU wide from the 1st of January… Read more

2015-06-10

NEW CHIEF OPERATIONS OFFICER (COO) TO I-TECH

Mintage Scientifics holding I-Tech strengthens its commercial and industrial capabilities by appointing Oliver Weigenand as Chief Operating Officer (COO). Read more

2014-09-12

I-TECH’S SELEKTOPE® APPROVED IN CHINA

I-Tech has been notified that Selektope®, a marine biocide used to improve ship hull performance and reduce maintenance, has been approved for use in China Read more

2014-07-08

I-Tech signs supply agreement with Chugoku marine paints Ltd

I-Tech has entered into a non-exclusive supply agreement with Chugoku Marine Paints Ltd (CMP) for use of I-Tech’s proprietary product, Selektope®, in commercial antifouling paints.… Read more

2014-04-09

I-Tech´s Selektope® recommended for EU approval by the UK Health and Safety Executive (HSE)

Mintage Scientifics minority interest holding, I-Tech, the originator of Selektope®, a marine biocide used to improve ship hull performance and reduce maintenance, has been notified… Read more

2012-12-20

Vicore Pharma receives funding for development of angiotensin AT2-receptor agonists for potential treatment of multiple sclerosis

Vicore Pharma today announced funding support from Fast Forward, LLC. The funding award will help support the research of angiotensin AT2-receptor agonists for the potential… Read more

Load more
2019-11-13 | Regulatory

Vicore Pharma has completed a directed share issue of approximately SEK 125 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, THE UNITED KINGDOM, CANADA, HONGKONG, JAPAN, SWITZERLAND, NEW ZEALAND, SINGAPORE, SOUTH AFRICA,… Read more

2019-11-12 | Regulatory

Vicore Pharma intends to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, THE UNITED KINGDOM, CANADA, HONGKONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, THE… Read more

2019-11-08 | Regulatory

Interim report January-September 2019

Gothenburg, November 8, 2019 - Vicore Pharma Holding AB (publ) publish the interim report for the third quarter 2019.  Read more

2019-10-03 | Regulatory

Vicore Pharma announces the Nomination Committee for the 2020 Annual General Meeting

Gothenburg, October 3, 2019 – Vicore Pharma Holding AB (publ) has appointed the Nomination Committee for the 2020 Annual General Meeting. The three largest shareholders… Read more

2019-09-16 | Regulatory

Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

Gothenburg,September 16, 2019- On September 11, 2019, Vicore Pharma Holding AB (publ) (”Vicore” or the “Company”)  announced that Nasdaq Stockholm’s listing committee had approved that the Company’s… Read more

2019-09-11 | Regulatory

Vicore Pharma has been approved for listing on Nasdaq Stockholm

Gothenburg, September 11, 2019 – Nasdaq Stockholm’s listing committee has approved Vicore Pharma Holding AB (publ)’s (”Vicore”) application to be listed on Nasdaq Stockholm’s main… Read more

2019-08-23 | Regulatory

Interim report April-June 2019

Mölndal, August 23, 2019 – Vicore Pharma Holding (publ) publish the interim report for the second quarter 2019. Read more

2019-05-15 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) (”Vicore Pharma”) on 15 May 2019. Read more

2019-05-15 | Regulatory

Interim report January - March 2019

Mölndal, May 15, 2019 – Vicore Pharma Holding (publ) publishes the interim report for the first quarter 2018. Read more

2019-04-23 | Regulatory

Vicore Pharma announces systemic sclerosis as the second indication for VP01

Mölndal, April 23, 2019 - Vicore Pharma AB (publ) a leading rare diseases pharmaceutical company today announces that it has selected diffuse systemic sclerosis (dSSc)… Read more

2019-04-12 | Regulatory

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, with registered office in Mölndal, are summoned to the Annual General Meeting on Wednesday… Read more

2019-04-12 | Regulatory

Vicore Pharma's Annual Report 2018 published

Mölndal, April 12, 2019 - Vicore Pharma Holding AB (publ) announces today that the annual report for 2018 has been published and is available on… Read more

2019-03-15 | Regulatory

Year-end report 2018

Mölndal, March 15, 2019 – Vicore Pharma Holding (publ) (ticker: VICO) publish the year-end report for 2018 Read more

2018-11-30 | Regulatory

Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)

The shareholders in Vicore Pharma Holding AB (publ), reg. no. 556680-3804 (the “Company”), are hereby summoned to attend an Extraordinary General Meeting (“EGM”) on Monday… Read more

2018-11-30 | Regulatory

Vicore Pharma’s Board of Directors has resolved on a directed share issue of around SEK 160 million to finance the continued development of the drug development programs VP01 and VP02

NOT FOR DISTRIBUTION OR PUBLIC RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UK, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN… Read more

2018-11-08 | Regulatory

Interim report July-September 2018

Mölndal, November 8, 2018 – Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the third quarter 2018. Read more

2018-10-22 | Regulatory

Göran Wessman resigns from the Board – joins the Nomination Committee now appointed in Vicore Pharma Holding

Mölndal, October 22, 2018 - Due to personal reasons, Göran Wessman has chosen to resign from the Board of Directors of Vicore Pharma Holding AB… Read more

2018-10-09 | Regulatory

Rights issue in Vicore oversubscribed by 33 percent – The company receives SEK 82.4M

Mölndal, October 9, 2018 - Vicore Pharma Holding AB (publ) (”Vicore” or the ”Company”) has completed the new share issue with pre-emption rights for existing… Read more

2018-09-10 | Regulatory

Vicore Pharma expands VP01 (C21) clinical program to enable functional read out

Vicore Pharma (publ) today announced that it will expand its clinical program of lead compound C21, for the treatment of idiopathic pulmonary fibrosis (IPF), to… Read more

2018-08-30 | Regulatory

Carl-Johan Dalsgaard Appointed New CEO of Vicore Pharma

The board of directors of Vicore Pharma Holding AB (”Vicore”) has on August 29, 2018 appointed Dr. Carl-Johan Dalsgaard as new CEO of Vicore. Carl-Johan… Read more

2018-08-24 | Regulatory

Interim report April-June 2018

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the second quarter 2018. Read more

2018-08-13 | Regulatory

Press release from the Extra General Meeting August 13, 2018

The Extra General Meeting (EGM) of Vicore Pharma Holding AB (publ) was held today August 13, 2018. The EGM passed resolutions regarding, among other thing,… Read more

2018-07-03 | Regulatory

Vicore Pharma and HealthCap create a leading drug development company focused on severe lung diseases

Vicore Pharma Holding AB (publ) ("Vicore" or "The Company") has entered into an agreement to acquire INIM Pharma AB ("INIM"), a Swedish biopharmaceutical company developing… Read more

2018-05-11 | Regulatory

Summons to attend the Annual General Meeting of Vicore Pharma Holding AB (publ).

The shareholders in Vicore Pharma Holding AB (publ), 556680-3804, are hereby summoned to attend the Annual General Meeting on June 13, 2018 at 4:00 p.m.… Read more

2018-05-08 | Regulatory

Interim report January-March 2018

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the first quarter 2018. Read more

2018-04-18 | Regulatory

Vicore Pharma receives approval to start Phase IIa study in IPF

Vicore Pharma Holding (publ) (ticker: VICO) today announces the approval from the British Medicines Agency MHRA and the Ethics Committee for London and Surrey to… Read more

2018-04-12 | Regulatory

Vicore Pharma publish annual report for 2017

Vicore Pharma Holding (publ) (ticker: VICO) can today announce that the annual report for 2017 is now available on the company's website; www.vicorepharma.com Read more

2018-04-06 | Regulatory

Summons to attend the Annual General Meeting of Vicore Pharma Holding AB (publ)

The shareholders in Vicore Pharma Holding AB (publ), 556680-3804, are hereby summoned to attend the Annual General Meeting on Tuesday, May, 8, 2018 at 3:00… Read more

2018-02-21 | Regulatory

Year-end report 2017

Read more

2018-02-08 | Regulatory

Vicore Pharma acquires shares in I-Tech

Vicore Pharma Holding AB (publ) (ticker: VICO) announces a share increase in I-Tech AB. Read more

2017-12-22 | Regulatory

Vicore Pharma increases its holding in I-Tech AB

Vicore Pharma Holding (publ) (ticker:VICO) has increased its holding in I-Tech through a share issue. Read more

2017-12-22 | Regulatory

Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding (publ) (ticker:VICO) announces that an application to start a Phase IIa study with C21 in patients suffering from Idiopathic Pulmonary Fibrosis has… Read more

2017-11-08 | Regulatory

Vicore Pharma´s board member Göran Arvidson has passed away

Vicore Pharma Holding (publ) (ticker:VICO). It is with great regret we today inform of board member Göran Arvidson sudden and unexpected death. Read more

2017-10-19 | Regulatory

Interim report July-September 2017

Vicore Pharma Holding publish the interim report for the third quarter, 2017. Read more

2017-10-02 | Regulatory

Phase I extension study demonstrates beneficial effects on lipid metabolism with C21

Vicore Pharma AB (publ) (ticker: VICO) can today announce positive results from the in-depth analysis of the Phase I extension study with its candidate drug… Read more

2017-08-24 | Regulatory

Interim report April-June 2017

Vicore Pharma Holding publish the interim report for the second quarter, 2017. Read more

2017-08-17 | Regulatory

Results from extension study with C21 show safety, tolerability and indicate effects on lipid metabolism

Vicore Pharma AB (publ) (ticker: VICO) can today announce positive results from the Phase I extension study with its candidate drug C21. Read more

2017-06-01 | Regulatory

Vicore Pharma makes strategic recruitments

Vicore Pharma AB (publ) (ticker: VICO) today announced that they strengthen the organization with three new key recruitments. Read more

2017-05-17 | Regulatory

Newly appointed Chairman of the Board increases his holdings in Vicore Pharma Holding

Newly appointed Chairman of the Board of Vicore Pharma Holding (ticker: VICO), Leif Darner has acquired 100,000 shares from Protem Wessman AB, controlled by Göran… Read more

2017-05-10 | Regulatory

Press release from the Annual General Meeting May 10, 2017

The Annual General Meeting (AGM) of Vicore Pharma Holding AB (publ) was held today May 10, 2017. The AGM passed resolutions regarding, among other thing,… Read more

2017-05-10 | Regulatory

Interim report January-March 2017

Vicore Pharma Holding publish the interim report for the period January-March, 2017. Read more

2017-04-06 | Regulatory

Vicore Pharma Holding publish annual report for 2016

We achieved the milestones we determined for 2016. Now, we will continue to develop C21 into a future drug for the treatment of idiopathic pulmonary… Read more

2017-04-03 | Regulatory

Notice of Annual General Meeting in Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, hereby gives notice to shareholders to attend the Annual General Meeting on Wednesday 10 May 2017 at… Read more

Load more